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Abstract
Background: Despite recent advances in early detection and improvements in chemotherapy for colon cancer, the
patients still face poor prognosis of postoperative recurrence and metastasis, the median survival for patients
with metastatic colorectal cancer is approximately 22–24 months. Some immunotherapeutic approaches had
been attempted in colon cancer patients to significantly increase overall survival. A vaccine based approach
has shown a novel direction for colon cancer prevention and therapy.
Methods: In this study, the experiments were designed including prevention and therapeutic stages in order to attain
effect against tumor recurrence in clinical settings. The anti-tumor efficacy of a novel cytokine adjuvant vaccine that
contained cytokines GM-CSF and IL-2 and inactivated colon CT26.WT whole cell antigen was evaluated in BALB/c mouse
tumor models by measuring tumor growth post vaccination and the survival time of tumor-bearing mice, analyzing the
expression and distribution of CD4, CD8, CD11c, CD80, CD86 and CD83 positive cells in control and treated mice by flow
cytometry and immunochemistry. The tumor-specific cytotoxic T cells (CTL) were analyzed by tumor proliferation and
the lactic dehydrogenates (LDH) release assays. IFN-γ, IL-2 and GM-CSF secretion in serum was assayed by ELISA.
Results: Our results suggested that cytokine adjuvant vaccine significantly inhibited tumor growth and extended
the survival period at least 160d. It was found that the levels of CD8 + T and the tumor-specific cytotoxicity were
significantly higher in prevention and treatment group vaccinated by cytokine adjuvant vaccine. CD8 + T cells
play a key role in anti-tumor response.
Conclusions: The novel GM-CSF and IL-2 based adjuvant vaccine effectively activated autologous T-cell response
and represented a promising immunotherapeutic approach for patients with colon cancer.
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Background
Colon cancer is a common malignant tumor of the di-
gestive tract [1]. It remains a challenge to treat advanced
colon cancer due to postoperative recurrence and metas-
tasis. Currently, surgical resection of primary colorectal
lesions combined with adjuvant chemotherapy and radi-
ation continues as the mainstay of therapy [2]. Unfortu-
nately, around 30 % of colorectal carcinoma patients are
diagnosed with metastatic disease at initial presentation,
and an additional 25–30 % subsequently develops
metastatic disease [3, 4]. Despite recent advances in early
detection and improvements in chemotherapy, the me-
dian survival for patients with metastatic colorectal can-
cer is approximately 22–24 months, with 5-year survival
less than 5 %. Recently, additional immunotherapeutic
approaches such as cytokine, cytokine-induced killers
(CIK), mAb and tumor vaccine therapy in patients with
advanced colon cancer significantly increase overall sur-
vival [5–8]. Moreover, these approaches also showed to
be safe and effective. Amongst these, therapeutic tumor
vaccines showed some promise. For example, preclinical
studies demonstrated an enhanced antitumor activity of
granulocyte–macrophage colony-stimulating factor
(GM-CSF) or IL-2 producing murine colon tumor cell
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vaccines [9, 10] and each cytokine have been used as an
adjuvant with cancer vaccines [11, 12]. Nevertheless, so
far the treatment with vaccines failed to significantly im-
prove the 5-year survival of patients with colon cancer.
Therefore, a new adjuvant therapeutic vaccine is needed.
GM-CSF is an important growth and differentiation
factor for dendritic cells, which are potent antigen-
presenting cells that can take up cellular proteins as
tumor antigens [13]. For an effective antitumor response,
preclinical studies suggested that GM-CSF secretion
occur at the site of vaccination and high levels of the
cytokine must be sustained for several days [14, 15].
GM-CSF-producing vaccines, together with autologous
or allogeneic tumor cells, were frequently tested in pre-
clinical and clinical studies [16–18], and antitumor
responses were observed in various models such as clin-
ical trials with pancreatic cancer patients [19–21]. Thus,
a GM-CSF producing bystander cell line significantly
improved the feasibility and efficacy of autologous or
allogeneic tumor vaccines in human studies. IL-2 is a
principle cytokine responsible for the differentiation of
effector T cells. Relevant studies indicated that targeting
IL-2 to tumor cells facilitated their elimination via
enhanced T cell activation [9]. Therefore, IL-2 has the
potential to aid in eliciting anti-tumor responses. Several
studies suggested that IL-2 can be used in tumor vac-
cines, where it enhanced the antitumor response against
several cancers [22, 23].
In the present study, we evaluated the efficacy of cyto-
kine adjuvant (recombinant mouse GM-CSF and IL-2)
vaccine pulsed with inactivated CT26.WT colon tumor
cells via measuring the tumor-specific CTL activity and
associated anti-tumor effect in a colon cancer model.
Methods
Animals and cells
Female and male BALB/c mice, 6 weeks old were pur-
chased from the Beijing Experiment Animal Center,
Chinese Academy of Sciences (Beijing, China). 130 mice
were used for preliminary experiment, and 240 mice were
used for formal experiment. All mice were kept under
pathogen-free conditions in the animal center of the Harbin
Medical University (Harbin, China). CT26.WT, a mouse
colon adenocarcinoma cell line was purchased from the
Shanghai Cell Biology Institutes, Chinese Academy of Sci-
ences (Shanghai, China) and was cultured in RPMI medium
1640 (Hyclone, China) containing 10 % heat-inactivated
fetal calf serum (FCS), 2 mmol/L glutamine, penicillin G
(100U/mL), and streptomycin (100 μg/mL) at 37 °C in a
humidified incubator supplemented with 5 % CO2.
Tumor model and vaccine production and immunization
To establish the tumor model, CT26.WT tumor cells
(5 × 105cells per mouse) were injected subcutaneously
into the neck of BALB/c mice. Tumors were observed
after 8 days of cells inoculation in control mice. The
cytokine adjuvant vaccine consisted of the following
components: (1) GM-CSF & IL-2 cytokines (R & D,
USA) adjuvants prepared by heparin and HSA (human
serum albumin) package (4500 IU/30 μl) and (2)
CT26.WT tumor cells that were inactivated by mitomy-
cin C (MMC) (Fuji Plant, Japan) for 2 h and then mech-
anically digested and counted. Finally, each vaccine dose
was constituted by mixing 30 μl of each, GM-CSF and
IL-2 as well as 40 μl of inactivated CT26.WT tumor cells
(1 × 106 cells). The cytokine adjuvant vaccine was
immunization subcutaneously into the underarm and
foot-pad of BALB/c mice for different times.
Lymphocytes isolation and FACS analysis
Lymphocyte cells were isolated from lymph nodes by
manual dissociation and were suspended in Hanks buffer
(Sigma, China). T cells were further purified by CD3
microBeads (Miltenyi Biotech, Germany) and counted.
Splenocytes were isolated and treated with ACK red
blood cell lysis buffer (Invitrogen, China) following man-
ual dissociation, and then the similar protocol was used
for isolation of as described above. Finally, lymphocytes
(1 × 106) were stained with FITC-conjugated mAbs
against mouse CD4 or CD8 and PerCP-Cy™5.5-conju-
gated against mouse CD3, all purchased from BD Phar-
mingen (BD, USA). Next, these stained cells were
analyzed using a FACS Caliber flow cytometer (BD,
USA) and the Cell Quest software package (BD, USA).
Cytotoxic T lymphocyte activity assay and cytokines
detection
To confirm the tumor-specific activity of cytotoxic T
lymphocytes (CTLs), T lymphocytes were extracted at
different time points. CD3+ T cells were isolated using
CD3 microBeads (Miltenyi Biotech, Germany). CD8+ T
cells were obtained by flow cytometry using anti-CD4
antibody by negative selection. Purified CD8+T cells
from each group of mice were cultured in RPMI 1640
medium containing 10 % FCS. Next, effector T cells
were mixed and incubated with target CT26.WT cells in
a 96-well plates (E: T, 50:1) optimization for 24 h. There-
after, the supernatant from each well was collected and
the cytolytic activity was measured by a LDH cytotox-
icity detection kit (Nanjing jiancheng, China). For meas-
uring CTL activity, we used the MTT cell viability
detection kit (Sigma, China). The target CT26.WT cells
were added into 96 well plates over night, and effector
T cells suspensions were added in E: T ratio of 50:1
optimization. The serum samples of each group of mice
were collected and stored at −80 °C. The cytokines,
IFN-γ, IL-2 and GM-CSF levels were detected by using
mouse cytokine ELISA Kit (RayBio®, USA).
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Immunohistochemical staining analysis
Lymph nodes and tumors from each group were col-
lected, fixed, embedded in paraffin, and sections stained
for CD4, CD8, CD11c, CD80, CD86 and CD83 markers
(Bioss, China) using the immunohistochemical staining
kit (Santa, USA). Briefly, the sections were incubated
with specific antibodies using a 1:200 dilution and subse-
quent detection with EnVison detection system (DAKO).
Staining scores were quantified using IHS (IHS = A × B,
A stands for positive cells percentage in five visions, B
stands for staining intensity for positive cells) [24]. The
H & E staining for tumor were referenced by histological
and histochemical methods [25].
Statistical analysis
The differences between groups were evaluated using
Statistical Package for Social Science 20 (SPSS20.0). Stat-
istical analysis was performed using a Student’s t test
and survival differences among different groups of mice
were evaluated with a log-rank test of the Kaplan-Meier
survival curves. The statistical tests were two tailed and
p values < 0.05 were considered to be statistically
significant.
Results
Optimization of the mouse tumor model and experimental
design
The schematic vaccine preparation and subsequent func-
tional mechanisms for the induction of autologous T-cell
anti-tumor response in a mouse colon cancer model is
depicted in Additional file 1: Figure S1. Before analyzing
treatment efficacy of the cytokine adjuvant vaccine,
extensive standardization of different parameters to
develop an ideal tumor model was applied, including the
assessment of tumor formation time and volumes
(Fig. 1a), specific anti-tumor effect of the vaccine
(Fig. 1b), comparisons of tumor sizes between male and
female mice (Fig. 1c), and optimized doses of inactivated
tumor whole cell antigen in the vaccine (Fig. 1d). The
results revealed that, there was no significant effect on
the use of adjuvant or inactivated antigen alone, inacti-
vated antigen obtained from 1 × 106 tumor cells in the
vaccine had the most significant effect on inhibition of
tumor development in the female mice that subcutane-
ously injected with 5 × 105 tumor cells. The tumor mass
was generally established within 7–10 d post injection of
the tumor cells. Based on these optimization steps, we
compared the preliminary results of cytokine adjuvant
vaccines between GM-CSF group, IL-2 group and GM-
CSF + IL-2 group by observing the survival period. The
results revealed that combined application extended the
survival period and significantly inhibited the tumor
growth compared to single group (Fig. 1e). Then we fur-
ther examined treatment efficacy and mechanism of the
cytokine adjuvant vaccination in a BALB/c mice colon
cancer model. We divided the experimental procedures
into the preventive and therapeutic stages, which may
further strengthen anti-tumor effect during the course of
tumor recurrence in clinical settings (Fig. 1f ).
Cytokine adjuvant vaccine enhanced anti-tumor immunity
in the prevention and therapeutic models
Then, we set up the tumor model by subcutaneously in-
jection of CT26.WT colon cancer cells (5 × 105) at day 0.
In order to determine if the vaccine had a preventive or
therapeutic potential during tumor progression, firstly,
we vaccinated the mice in the Prevention group twice, at
10 d (d − 10) and 3 d (d − 3) before tumor cell injection;
secondly, in the Treatment group, respective twice vacci-
nations were given before and after tumor cell injection
(d − 10, d − 3, d + 7, d + 14). The data showed that,
whereas the weight of mice was not affected by vaccine
inoculation (data not shown), the tumor growth as ana-
lyzed by tumor volumes and weights, was significantly
inhibited in both groups of the vaccinated mice as com-
pared to that in the controls. While 14 out of 14 (100 %)
mice in the control group developed heavy tumors, only
6 out of 14 mice (42.8 %) and 2 out of 14 mice (14.3 %)
in respective Prevention and Treatment groups had sig-
nificantly less heavy tumors (Fig. 2a and b). As seen in
Fig. 2c, Tumor group mice at 49 d post tumor cell injec-
tion had an average tumor volume and weight of 18.17
± 3.94 cm3 and 10.48 ± 2.65 g respectively, Prevention
group mice that were vaccinated two times had an aver-
age tumor volume and weight of 9.58 ± 0.36 cm3 and
5.97 ± 0.34 g whereas the Treatment group mice that
were vaccinated four times had an average tumor vol-
ume 3.48 ± 0.43 cm3 and weight of 2.14 ± 0.21 g (p <
0.01). Furthermore, in comparison to the control group,
the tumor inhibition rate was respective 57.1 % and
85.7 % in the Prevention and Treatment group. In
addition, the survival rate was also assessed in the Con-
trol, Prevention and Treatment groups that each con-
tained 20 mice, until 160 d post tumor cell injection.
The data showed that mice in the Treatment group had
greatly prolonged survival as compared with the Control
group and Prevention group (Fig. 2d, p < 0.001). Taken
together, these results indicated that vaccine was vacci-
nated four times including prevention and therapeutic
stages were better than vaccinated two times. Then we
discussed the mechanism between Tumor group and
Treatment group for repeating experiment.
Variation of CD4 + and CD8+ T cell populations in
peripheral lymphoid organs
To further reveal variations of CD4+ and CD8+ T cells
in the vaccinated and control mice, we stained the iso-
lated CD3 + T cells from the draining LN and SP with
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specific anti-CD4 and -CD8 antibodies and examined
their expression by FACS. The statistical results showed
that the fluctuation of CD4/CD8 cell ratios during tumor
progression after vaccination was significant and may re-
flect more rigorous and dynamic immune regulation and
activity in the Treatment group (Fig. 3Aa and Bc). More-
over, ratios of CD8/CD3 cells in Treatment group was
higher than the Tumor group in all time points in LN and
in time points d-7 to d + 13 in SP (Fig. 3Ab and Bd). Then
we found that the mice from the Treatment group were
Fig. 1 Standardization of the tumor model and its tentative mode of action The animals were vaccinated for two times before injected tumor cells during
pre-experimental stage. Panel (a), shows the tumor growth after day 0, 10 and 30, as a result of subcutaneous injection of CT26.WT tumor cells into the
neck of BALB/c mice. Panel (b), depicts the efficacy of cytokine adjuvant vaccine, where each group with 5 mice was vaccinated twice at interval of 7 and
3 days, before subcutaneous injection of CT26.WT cells. Panel (c), shows the comparison between male and female mice in terms of tumor uniformity.
Panel (d), represents the standardization of inactivated antigen for effective anti-tumor response. M stand for million, * stand for Optimization. Panel (e),
represents the effect of combination application compared to single group by observing survival period, which each group with 15 mice was vaccinated
twice before subcutaneous injection of CT26.WT cells. *denotes p< 0.05, ***denotes p< 0.001. Panel (f), The experiment timeline showing the times of
vaccinated. In order to establishing the tumor recurrence model stimulating the clinical status, the experiment was divided into prevention stage and
therapeutic stage. The Prevention group was vaccinated vaccine for two times in prevention stage, the Treatment group was vaccinated vaccine for four
times include prevention stage and therapeutic stage, and the Tumor group vaccinated inactivated antigen for control. All groups were inoculated tumor
cells at the same time. Tumor inoculation was the initial point (day 0)
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not able to form tumors when they were re-inoculated
with the tumor cells (data not shown). The results indi-
cated that T cell immune memory formed after vaccin-
ation protecting against tumor attacks. Furthermore, we
detected the ability of the tumor-specific T cells.
Vaccination enhanced the tumor-specific CTL responses
We further analyzed whether such a cytokine adjuvant
vaccination enhanced tumor-specific CTL response.
LDH assay was performed to analyze the cytotoxic
effect. The results demonstrated that CD8 + T cells iso-
lated from draining lymph nodes and the spleen of the
vaccinated mice resulted in induction of higher LDH
release by CT26.WT tumor cells in all time points in the
Treatment group (Fig. 4a). In addition, the CTL activity
was also examined by analyzing the target cell prolifera-
tion. The results showed that CT26.WT tumor cell
proliferation was significantly reduced in samples that
had CD8 + T cells from LN and SP of Treatment groups,
at all time points as observed in Fig. 4b. These data sug-
gested that CD8 + T cells isolated from the vaccinated
mice were more effective in generating CTL response.
Next, we analyzed the levels of cytokines IFN-γ, IL-2 and
GM-CSF most probably produced by activated T cells in
serum. The data from different time points suggested that,
the Treatment group had significantly periodic increases
in the IFN-γ and IL-2 levels as compared to the tumor
group (Fig. 4c). Both cytokine levels peaked 2 d and 6 d
post tumor cell inoculation and were significant higher in
the vaccinated mice (p < 0.05). The levels of GM-CSF in
serum in Treatment group were higher than the Tumor
group which may stand for immune status for presenting
antigen (Additional file 2: Figure S2). Collectively, this data
suggested that the autolougous T-cell response were
effectively elicited and significantly stronger in the Treat-
ment group.
Analysis on distribution of CD4, CD8, CD11c, CD80, CD86
and CD83 cell populations in lymph nodes and tumor
tissues
We next analyzed distribution of CD4, CD8, CD11c,
CD80, CD86 and CD83 cells in the lymph nodes by IHC
in order to confirm the FACS results (Fig. 5A, and B).
Consistently, we confirmed that, as compared to the
Tumor group, the samples in Treatment group had
greatly higher expression of CD4, CD8 and CD11c, sug-
gesting a strong immune response that induced by the
vaccination in the Treatment group (Additional file 3:
Figure S3). It is interesting to note that the expression of
CD8 and CD11c in the Treatment group maintained
Fig. 2 Preliminary effect of the cytokine adjuvant vaccine Panel (a), shows the pictures of mice with tumors at day 49 from three different
groups. Panel (b), shows the pictures of tumors excised from each group of mice and subsequently these tumors were used to calculate the
tumor inhibition rate. Panel (c), represents the comparison of tumor volume (left) and weight (right) between tumor, prevention and treatment
group. Panel (d), depicts a survival curve analyzed with a log-rank test of Kaplan-Meier curves using mice from Tumor (control), Prevention and
Treatment group, where 20 mice of each group were followed for a period of 160 d (Kaplan Meier, p < 0.001). ***denotes p < 0.001
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significantly higher than that in the control group during
the tested period of time (Fig. 5A b and c). The level of
CD11c expression may represent the relative amount of
mature DC and effective antigen presentation (Fig. 5Ac).
In order to further confirm our results, specific surface
molecules of CD80, CD86 and CD83 on DC cells were de-
tected. The results showed that the different variable for
three molecules (Fig. 5B and Additional file 4: Figure S4).
There is no significant difference except for a few time
points for the levels of CD83 during the Tumor group and
Treatment group (Additional file 4: Figure S4C). However,
the levels of CD80 were higher than the levels of CD86 in
lymph nodes. Furthermore, the expressions of CD80 and
CD86 in Treatment group were significantly higher than
Tumor group especially on the back of a few time points
the same as the results of CD11c (Fig. 5B a and b). The re-
sults suggested that GM-CSF could induce activation and
maturation of DC and maintain at relevantly high levels
during the course. These data suggested that the vaccine
may induce the body to produce a stronger T cell response
due to higher number of mature DCs in the lymph nodes.
Moreover, we compared distribution of CD4+ T&
CD8+ T cells in the tumor tissues in different groups.
Firstly, HE staining revealed that, in comparison to the
tumor group whose tumors were more concrete, tumor
tissue samples had significantly wider spread of tissue
damage in the Treatment group, in which we further
observed greater infiltration of the lymphocytes into the
tumor tissues. Noticeably, the CD8+ T cells in the Pre-
vention and Treatment groups tended to accumulated in
the damaged area (Fig. 5C). However, the number of
CD4+ cells in the Tumor group was higher than the
Treatment group and were located around the tumor
cells. These cells may aid tumor growth by behaving as
regulatory T cells with an immuno-suppressive function.
Such a phenomenon warrants further investigations.
Discussion
In this study, we demonstrated safety and feasibility of a
cytokine adjuvant vaccine in a mouse colorectal cancer
model. To our best knowledge, this is the first study
with a combination of the cytokines GM-CSF and IL-2
as a potent adjuvant of the vaccine that was applied in
colon cancer models. Our data suggested that treatment
with the cytokine adjuvant vaccine significantly delay or
eradicate formation of colon cancer in this model. Thus,
the vaccine and methodology may further used as cancer
immunotherapeutic strategies to improve clinical recur-
rence after surgery.
It is shown that a sustained level of GM-CSF and IL-2
at the vaccination site is important for the activation of
anti-tumor immune response [13], as GM-CSF acts to
recruit DCs to present antigen, and IL-2 strengthens the
T-cell response. Consistently, we showed that, if given
sufficient amount in the colorectal cancer model, the
vaccine may release GM-CSF and IL-2 in a good timing
and effectively elicited an autologous T cells response,
which achieved high efficacy in preventing from the
tumor formation. Furthermore, there was a significant
difference on the anti-tumor response in vivo between
Fig. 3 Variation of CD4+, CD8+ cell populations in peripheral lymphoid organs Panel A, depicts the CD4/CD8+ and CD8/CD3+ ratios as analyzed
by flow cytometry analysis from the Lymph node, LN (a, b) Panel B, depicts the CD4/CD8+ and CD8/CD3+ ratios as analyzed by flow cytometry
analysis from the Spleen, SP (c, d), isolated from Tumor (control) and Treatment group mice at an interval of 3–4 d. *denotes p < 0.05,**denotes
p < 0.01, ***denotes p < 0.001
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therapies in the prevention and treatment group, which
adopted respective two and four times of the repeated
vaccination. These indicate that the timing and times of
vaccination procedures are important for an effective anti-
tumor response. As approximately half of the colon cancer
patients may suffer from tumor recurrence after surgery
[26], our data imply that, combination of the inactivated
resected tumor tissue as whole cell antigens and the cyto-
kine adjuvant with optimized vaccination procedures on
these patients may prevent from the tumor recurrence.
Yet further investigations are highly warranted.
Besides significantly stronger CTL activity and pro-
longed survival rates in the treatment group, we observed
greatly reduced ratios of weight/volume of the tumor mass
in the treatment as compared to tumor group. The tumor
mass in the treatment group mice were severely damaged
and not as solid as that in the tumor group, in addition to
our IHC analysis with an anti-CD8 antibody staining, we
speculate that enhanced infiltration of the tumor specific
T lymphocyte may contribute to such a phenomenon
[27]. Furthermore, the levels of IFN-γ in serum play an
important role in increased anti-tumor immune responses
[28]. We found higher levels of IFN-γ in the serum of vac-
cinated mice. Moreover, IHC analysis of the lymph nodes
showed higher levels of mature DC in the treatment
group, which may provide specific antigen-MHC com-
plexes for effective T cell response. Further IHC data with
tumor tissues indicated that, the tumor group had a
higher number of CD4+ T cells, whilst the number of
CD8+ T cells was higher in the treatment group. Such
Fig. 4 Tumor specific CTL activity in peripheral lymphoid organs and cytokines secretion in the serum The peripheral immune organs (LN and SP)
were collected (3 mice/per group), and CD3+ T cells were isolated. These cells were incubated with CT26.WT tumor cells. Panel (a), represent the
LDH release induced by T cells isolated from LN (left) and SP (right) of tumor control or treatment group mice. Panel (b), represents the CT26.WT
tumor cell proliferation as measured by MTT assay post incubation with effector T cells at an E: T ration of 50:1. Panel (c), represents the secretion
of cytokines measured by ELISA kit from the serum of tumor control and treatment group mice. Data are represented as mean ± SD. *denotes
p < 0.05,**denotes p < 0.01, ***denotes p < 0.001
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results may show that the effector T cells may display
either anti-tumor or tumor-suppressive effect in different
groups of animals [29]. Nonetheless, more specified mech-
anisms of the vaccine in vivo and its application to other
types of tumor models are ongoing in our lab; if the data
are confirmed, we will further test the effect in relevant
clinical studies.
Conclusion
In summary, our data demonstrated that the cytokine
(GM-CSF & IL-2) adjuvant vaccine had a significant
anti-tumor effect in colon cancer of a mouse model.
These results suggest that the effect maybe due to acti-
vating autologous T-cell response and an evaluation of
such a vaccine in other cancer models and colon cancer
patients is warranted to further test its immunothera-
peutic efficacy.
Additional files
Additional file 1: Figure S1. Provides schematic depiction of the
vaccine formulation. (PDF 124 kb)
Additional file 2: Figure S2. Provides the levels of GM-CSF in serum.
(PDF 209 kb)
Fig. 5 Distribution of CD4+, CD8+, CD11c+, CD80+ and CD86+ cell populations in Lymph node and tumor tissue Panel A, represents the
expression of CD4 (a), CD8 (b) and CD11c (c) as analyzed by IHC staining of LN isolated at different time points from tumor control or treatment
group mice. Panel B, represents the expression of CD80 (a) and CD86 (b) as analyzed by IHC staining of LN isolated at different time points from
tumor control or treatment group mice. The expression of these molecules was calculated by IHS. Panel C, represents the HE and anti-CD4 and
-CD8 IHC staining of tumor tissues collected from different groups. The results were observed in (40 × 10) horizon. Data are represented as mean
± SD. Bar = 50 μm. *denotes p < 0.05, **denotes p < 0.01, ***denotes p < 0.001
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Additional file 3: Figure S3. Provides the pictures for IHC staining for
CD4, CD8 and CD11c in lymph nodes. (PDF 298 kb)
Additional file 4: Figure S4. Provides the pictures for IHC staining for
CD80, CD86 and CD83 in lymph nodes. (PDF 445 kb)
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